Trabectedin in the treatment of soft tissue sarcoma: Real‐world data on effectiveness, safety, and financial implications from a European comprehensive cancer center
- 24 February 2026
- journal article
- Published by Wiley in International Journal of Cancer
- Vol. 159 (1) , 234-243
Abstract
Soft‐tissue sarcomas (STS) comprise over 150 histological subtypes, with advanced cases showing poor prognosis (5‐year survival n = 16), soft‐tissue leiomyosarcomas ( n = 17), and myxoid liposarcomas ( n = 8). Non‐L‐sarcomas (22%) included mostly synovial sarcomas. The overall disease control rate was 71%, with a median progression‐free survival (PFS) of 4.1 months, and an overall survival of 12.3 months. Subtype‐specific median PFS was 6.8 months for liposarcomas (11.3 for myxoid vs. 4.5 for other subtypes), 3.1 months for leiomyosarcomas (3.4 months for uterine vs. 3.1 for soft‐tissue), and 2.4 months for non‐L‐sarcomas. Patients received a median of 5 cycles (range: 1–38), with an average total dose of 16 mg [2–81], and an average hospital cost of €9900. Adverse events occurred in 91%, mainly hematological; cardiac toxicity was seen in 9%. This retrospective single‐center study in a limited cohort provides real‐world insights but should be interpreted with caution. Despite limited reimbursement, trabectedin may retain clinical utility, particularly in L‐sarcoma management.Keywords
This publication has 28 references indexed in Scilit:
- SELNET clinical practice guidelines for soft tissue sarcoma and GISTCancer Treatment Reviews, 2022
- Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆Annals of Oncology, 2021
- A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trialAnnals of Oncology, 2021
- Cemiplimab removed from reimbursable drugs in FranceEuropean Journal of Cancer, 2021
- Efficacy and safety of trabectedin for patients with unresectable and relapsed soft‐tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group studyCancer, 2019
- Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedinCancer, 2019
- A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcomaCancer Treatment Reviews, 2019
- A medico-economic study of trabectedin compared with end-stage treatment in soft tissue sarcomasJournal of Cancer Policy, 2017
- What makes real world outcomes in soft tissue sarcomas? A mono-institutional trabectedin experienceBulletin du Cancer, 2015
- Trabectedin in patients with advanced soft tissue sarcoma: A retrospective national analysis of the French Sarcoma GroupEuropean Journal of Cancer, 2015